Back to Journals » Cancer Management and Research » Volume 13

Extra-Hepatic Hepatoid Carcinomas in Female Reproductive System: Three Case-Reports with a Literature Review

Authors Liu Y, Zhou R, Wang S, Zhang G

Received 5 November 2020

Accepted for publication 28 January 2021

Published 17 February 2021 Volume 2021:13 Pages 1625—1636

DOI https://doi.org/10.2147/CMAR.S288913

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Harikrishna Nakshatri


Yao Liu,1,2 Ruiqi Zhou,1,2 Shourong Wang,1,2 Guiyu Zhang1,2

1Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong Province, People’s Republic of China; 2Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People’s Republic of China

Correspondence: Guiyu Zhang
Qilu Hospital of Shandong University, Wenhuaxi Road 107, Jinan, Shandong Province, People’s Republic of China
Tel +86 18560081737
Email zgy5566@sdu.edu.cn

Purpose: Hepatoid carcinoma of the ovary (HCO) and hepatoid carcinoma of the uterus (HCU) are rare malignancies that can be difficult to distinguish from other diseases such as hepatocellular carcinoma. In extremely rare cases, patients are negative for α-fetoprotein (AFP) by immunohistochemistry. Here we report 3 cases of HC of the female reproductive system, including 1 that was negative for AFP.
Patients and Methods: Three women aged 48, 56, and 67 years were treated at Qilu Hospital of Shandong University for HCO or HCU. We describe these cases in detail, including clinical features, diagnosis, treatment, and outcome, and review similar cases reported in the literature.
Results: All of our patients underwent surgery including hysterectomy and bilateral adnexectomy, and were treated with platinum-based chemotherapy. One patient died 3 months after the operation, and the other 2 are alive 22 and 63 months post surgery.
Conclusion: The first-choice treatment for HCO and HCU is staging surgery, which should be followed by platinum-based chemotherapy.

Keywords: HCO, HCU, therapy, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]